A U.S. cannabis company, Curaleaf Holdings Inc., has made a bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora has formed a special committee to review this unsolicited offer, which would result in the creation of a global cannabis entity operating in 17 countries across Europe, North America, and other regions.
Curaleaf, headquartered in Stamford, Conn., disclosed its intention to purchase all shares of Aurora after failed private negotiations with Aurora’s leadership. Despite sending formal letters of intent on June 23 and July 7 outlining its proposal, Curaleaf claimed that Aurora’s board did not engage in meaningful discussions. In response, Curaleaf plans to directly approach Aurora’s shareholders with an offer of $4 US per share, plus an additional $0.75 US in cash for each Aurora share.
Aurora confirmed receiving the letters from Curaleaf but disputed some aspects of the claims made by the U.S. company. While Aurora acknowledged the correspondence with Curaleaf’s CEO, it emphasized its commitment to executing its business plan and stated that discussions were not discouraged. Aurora will establish a special committee of independent directors to assess the proposal’s merits and its impact on stakeholders.
Despite the interest shown by Curaleaf, some analysts believe that the current offer undervalues Aurora’s long-term potential. They argue that Aurora’s market position in medical cannabis, product portfolio, financial strength, and regulatory expertise could lead to greater value creation in the future. Curaleaf, however, sees the merger as an opportunity to leverage its global distribution network with Aurora’s medical cannabis business, aiming to achieve significant cost synergies and enhance shareholder value.
The proposed deal between Curaleaf and Aurora, with combined revenues exceeding $1.5 billion US in the past year, is expected to bring about annual cost savings of at least $40 million US. Curaleaf’s CEO, Boris Jordan, views the merger as mutually beneficial, offering Aurora shareholders a chance to be part of a diversified global platform and capitalize on the favorable regulatory environment in the U.S.